Hegan et al. demonstrated that downregulation of PARP1 using small molecule inhibitors or siRNA resulted in the decreased expression of both BRCA1 and RAD51, two essential components in the HR pathway in various cancer types [148]. The gene discussed is BRCA1; the disease is cancer.